Stacking IGF-1 LR3 with BPC-157: a practical guide

The IGF-1 LR3 + BPC-157 stack is one of the few peptide combinations where both compounds earn their spot through complementary mechanisms rather than additive marginal benefits. IGF-1 LR3 supplies a long, systemic anabolic signal that supports muscle protein synthesis, satellite-cell activity, and recomposition. BPC-157 supplies local healing — angiogenesis, growth-factor recruitment, gut and connective-tissue repair — that protects the joints, tendons, and gut barrier from the increased stress of an anabolic phase. The two solve different problems, and their side-effect profiles don't overlap. That's why the stack works in practice and why it's become a staple for advanced users running serious recomp blocks.

What each compound brings

The case for the stack is easier to see when you separate what each peptide actually does.

IGF-1 LR3 is a long-acting analog of human IGF-1, modified to evade the IGF binding proteins that neutralize the native molecule. In circulation it produces a 6-hour anabolic signal at the IGF-1 receptor. The downstream effects:

• Increased protein synthesis at the muscle level
• Activation of satellite cells, supporting hypertrophy and fiber repair
• Improved nutrient partitioning toward muscle
• Some reduction in fasting glucose; meaningful hypoglycemia risk at higher doses
• Theoretical proliferative effects (anywhere IGF-1R is expressed)

BPC-157 is a 15-amino-acid peptide derived from gastric protective protein. It acts locally near the injection site to:

• Drive angiogenesis (new blood vessel formation)
• Recruit growth factors and accelerate tissue remodeling
• Strengthen tendon and ligament repair
• Heal gut barrier disruption — the visceral organ effects, not just musculoskeletal

The mechanisms don't overlap. IGF-1 LR3's signal is systemic and anabolic; BPC-157's signal is local and reparative. In a hard recomposition block, both pieces matter — you need the anabolic drive and you need the connective-tissue and gut support to handle the increased mechanical and metabolic stress.

Why the stack works for recomposition

A serious recomp phase puts simultaneous demands on the body. You're training hard, eating in a controlled way, pushing hypertrophy, and trying to protect joints, tendons, and the gut barrier from the wear of an extended progressive cycle. IGF-1 LR3 alone supports the anabolic side cleanly. The downside: the same anabolic signal that builds muscle also pushes connective tissue past where its remodeling rate can keep up, and IGF-1's effects on gut tissue are more variable than its effects on muscle.

BPC-157 closes the gap. It supports the connective tissue that's now being asked to handle bigger loads, and it backstops the gut against any IGF-1-related GI sensitivity. In community feedback, the most consistent observation is that users running IGF-1 LR3 alone hit a plateau around weeks 4–6 where joint or tendon issues — Achilles tightness, patellar tendinopathy, lower-back stiffness — start interrupting training. Adding BPC-157 from the start of the cycle prevents the issue from showing up.

For the broader IGF-1 LR3 mechanism and dosing context, see the IGF-1 LR3 pillar and recomposition with IGF-1 LR3: realistic expectations.

The standard stack protocol

The dosing community has converged on a fairly consistent protocol for the basic version of this stack:

A few details worth noting:

BPC-157 runs longer than IGF-1 LR3. Most users start both together but continue BPC-157 for 1–2 weeks past the IGF-1 LR3 stop. The reason: connective-tissue remodeling lags behind protein-synthesis changes, and the BPC-157 tail catches that.

Injection sites should differ. IGF-1 LR3 is dosed somewhere systemic and convenient (abdominal subQ is standard). BPC-157 is dosed near the tissue you're trying to support — calf for Achilles work, lower back for lumbar issues, near the elbow for triceps tendinopathy. Same syringe protocol, different anatomy.

Hypoglycemia management is non-optional. IGF-1 LR3 drops fasting glucose enough that the standard protocol includes a planned snack 30–60 minutes after injection. See hypoglycemia on IGF-1 LR3 for the practical management. This doesn't change because BPC-157 is added.

Variations worth knowing

The basic stack handles most use cases. A few common variations:

Add TB-500 for athletes with multi-site injuries. If recovery isn't localized to one spot, TB-500 layered onto BPC-157 + IGF-1 LR3 covers the systemic recovery angle. See comparing major recovery peptide protocols and can I stack BPC-157 with TB-500.

Add a GH secretagogue (ipamorelin + CJC-1295) for older users. Endogenous GH falls with age, and adding pre-bed ipamorelin/CJC-1295 supports the IGF-1 LR3's effects through complementary endogenous IGF-1 production. This makes more sense for users 35+ where natural IGF-1 levels have declined meaningfully.

Drop IGF-1 LR3 and use only BPC-157 if the goal is recovery, not recomp. The stack is for users actively pushing hypertrophy. Pure recovery cycles don't need IGF-1 LR3's systemic anabolic signal.

Side-effect profile of the combined stack

Most stack-related side effects come from the IGF-1 LR3 side; BPC-157 is largely neutral.

BPC-157 has its own well-tolerated profile — see why tired on BPC-157 for the most common minor effect. The combination doesn't produce additional emergent side effects beyond what either compound shows on its own.

Labs to pull before and after

The mandatory minimum for this stack:

• CBC — hemoglobin, hematocrit, platelets
• CMP — fasting glucose, kidney and liver markers
• Lipid panel — IGF-1 affects lipid metabolism modestly
• HbA1c if running multiple cycles — IGF-1 LR3 effects on long-term glucose handling

Optional but recommended:

• IGF-1 baseline — establishes pre-cycle level for comparison
• Total testosterone — for context on the anabolic-axis baseline
• DEXA or BodPod before and after — body comp endpoints are the actual reason you're running the stack

See baseline labs before a cycle for the broader lab framework.

Where the stack is and isn't appropriate

Appropriate for:

• Advanced lifters with at least one prior peptide cycle of either compound run successfully
• Users actively pushing hypertrophy or recomp goals, not generic recovery
• Athletes with both anabolic and connective-tissue recovery needs in the same training block
• Users who can manage hypoglycemia awareness reliably

Not appropriate for:

• First peptide cycle — start with BPC-157 alone or BPC-157 + TB-500 to establish baseline response. See easiest peptide for beginners
• Users without lab access for the standard before/after panel
• Anyone with personal or family history of cancer, particularly hormone-sensitive cancers — IGF-1 LR3's theoretical proliferative concern is not zero
• Pregnant or breastfeeding users — see peptides during pregnancy and breastfeeding

What to do

If you're going to run this stack, the practical sequence:

1. Pull baseline labs and body comp measurements. Don't skip this — the stack is expensive and the only way to evaluate effect honestly is against a measured baseline.
2. Source from a single vendor with current Certificates of Analysis on both compounds. Vendor variability is the most common reason stacks underperform expectations. See vendor due diligence checklist.
3. Start at the bottom of the dose ranges — IGF-1 LR3 30 mcg, BPC-157 250 mcg. Hold for one week before evaluating.
4. Manage hypoglycemia from day one. The first injection is when the glucose drop is most pronounced.
5. Run the IGF-1 LR3 portion 4–6 weeks, then continue BPC-157 alone for 1–2 weeks to catch the connective-tissue tail.
6. Pull post-cycle labs and comp measurements. Compare honestly. Decide based on data whether to repeat.

The IGF-1 LR3 + BPC-157 stack is one of the better-engineered combinations the strength-peptide community has converged on. The mechanisms are complementary, the side-effect profiles don't compound, and the protocol is straightforward. The reason it works isn't magic — it's that the two compounds were chosen because they solve different problems. That's worth more than stacking three peptides that all push the same pathway.

Related reading

• Recomposition with IGF-1 LR3: realistic expectations
• The rise and limits of IGF-1 LR3
• BPC-157 most studied recovery peptide
• Hypoglycemia on IGF-1 LR3
• Baseline labs before a cycle